BridgeBio Oncology Therapeutics, Inc. - 8-K Filing

BridgeBio Oncology Therapeutics announced new BBO-8520 data and strategic focus on KRAS-mutant cancers with $344.1 million in cash as of June 30, 2026. (Items: 8.01 Other Matters On September 8, 2026, BridgeBio Oncology Therapeutics, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)

SEC EDGAR · September 8, 2026, 20:19 UTC

Tickers: $BBOT

Read the full article at SEC EDGAR

More Regulatory news

XBiotech Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:53 UTC
Cohen & Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:48 UTC
UNITED BANCORP INC /OH/ - 10-Q Filing SEC EDGAR · November 12, 2026, 15:33 UTC
PATRIOT GOLD CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 15:32 UTC
First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC